P1106: PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS)

• M. Sun,
• J. Qi,
• Y. Song,
• K. Zhou,
• H. Liu,
• A. Shen,
• L. Geng,
• F. Zhou,
• J. Huang,
• Z. Chen,
• H. Zhang,
• M. Lu,
• M. Ahmad,
• L. Men,
• D. Yang,
• Y. Zhai,
• J. Wang

Affiliations

M. Sun

1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

J. Qi

1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Y. Song

2 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

K. Zhou

2 Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou

H. Liu

3 First Affiliated Hospital of University of Science and Technology of China (USTC) Anhui Provincial Hospital, Hefei

A. Shen

3 First Affiliated Hospital of University of Science and Technology of China (USTC) Anhui Provincial Hospital, Hefei

L. Geng

3 First Affiliated Hospital of University of Science and Technology of China (USTC) Anhui Provincial Hospital, Hefei

F. Zhou

4 Zhongnan Hospital, Wuhan University, Wuhan

J. Huang

4 Zhongnan Hospital, Wuhan University, Wuhan

Z. Chen

5 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China

H. Zhang

5 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China

M. Lu

6 Ascentage Pharma Group Inc., Rockville, United States of America

M. Ahmad

6 Ascentage Pharma Group Inc., Rockville, United States of America

L. Men

5 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China

D. Yang

7 State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Y. Zhai

6 Ascentage Pharma Group Inc., Rockville, United States of America

J. Wang

1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin